We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study.
- Authors
Huang, Zhuoying; Xu, Shuangfei; Liu, Jiechen; Wu, Linlin; Qiu, Jing; Wang, Nan; Ren, Jia; Li, Zhi; Guo, Xiang; Tao, Fangfang; Chen, Jian; Lu, Donglei; Wang, Yuheng; Li, Juan; Sun, Xiaodong; Wang, Weibing
- Abstract
We conducted a matched retrospective cohort study of two cohorts to estimate inactivated vaccine effectiveness (VE) and its comparative effectiveness of booster dose among older people in Shanghai. Cohort 1 consisted of a vaccinated group (≥1 dose) and an unvaccinated group (3,317,475 pairs), and cohort 2 consisted of a booster vaccinated group and a fully vaccinated group (2,084,721 pairs). The Kaplan–Meier method and Cox regression models were used to estimate risk and hazard ratios (HRs) study outcomes. For cohort 1, the overall estimated VEs of ≥1 dose of inactivated vaccine against SARS-CoV-2 infection, severe/critical Covid-19, and Covid-19 related death were 24.7% (95%CI 23.7%−25.7%), 86.6% (83.1%−89.4%), and 93.2% (88.0%−96.1%), respectively. Subset analysis showed that the booster vaccination provided greatest protection. For cohort 2, compared with full vaccination, relative VEs of booster dose against corresponding outcome were 16.3% (14.4%−17.9%), 60.5% (37.8%−74.9%), and 81.7% (17.5%−95.9%). Here we show, although under the scenario of persistent dynamic zero-Covid policy and non-pharmaceutical interventions, promoting high uptake of the full vaccination series and booster dose among older adults is critically important. Timely vaccination with the booster dose provided effective protection against Covid-19 outcomes. Inactivated COVID-19 vaccines have been widely used in China, but there is limited real-world evidence for their effectiveness in this setting. Here, the authors estimate effectiveness of inactivated vaccines for people aged 60 or older in Shanghai during a period when Omicron was the dominant circulating variant.
- Subjects
SHANGHAI (China); CHINA; BOOSTER vaccines; OLDER people; COVID-19 vaccines; COHORT analysis; VACCINE effectiveness
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-37673-9